Global respiratory disease testing market to gain USD 3.1 Billion by 2021 and increases with CAGR 3.6% between 2016 and 2021.
The report provides analysis and forecast for the respiratory disease testing market on a regional and global level. The study covers historic data of 2015 provided along with a forecast from 2016 to 2021 based on revenue (USD billion). The study provides restraints and drivers for the respiratory disease testing market coupled along with the impact they have on the demand over the forecast period. Moreover, the report also covers the analysis of opportunities present in the respiratory disease testing market on a global level.
With the objective to give the users of this report a complete and clear view on the respiratory disease testing market and to better understand the competitive landscape in the market, an analysis of Porter’s Five Forces model for the respiratory disease testing market has also been covered. The study provides with a comprehensive market attractiveness analysis, wherein product segments and end-user segments are based on their growth rate, market size, and general attractiveness.
The study provides a clear view on the respiratory disease testing market by segmenting the market based on end-user segment, product segment, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2015 to 2021. Based on product segment, the respiratory disease testing market has been segmented into imaging, spirometry, peak flow, blood gas, lung volume, and other tests. Based on the end-user segment, the respiratory disease testing market has been segmented into physician offices, hospitals, and clinical laboratories. The regional segmentation includes the current and forecast demand for Latin America, North America, Asia-Pacific, Europe, and the Middle East and Africa with its further bifurcation into major countries including Germany, France, UK, China, Japan, India, U.S. AND Brazil.
The report also includes comprehensive profiles of end players such as ndd Medical Technologies, Inc., Carestream Health, Inc., SDI Diagnostics, Nihon Kohden Corporation, CareFusion Corporation, Smiths Medical, COSMED, Perkin Elmer, Inc., Philips Healthcare, MGC Diagnostic Corporation, Futuremed America, Inc. GE Healthcare and others. The thorough description of players includes parameters such as company overview, business, financial overview, and recent developments of the company.
This report segments the global respiratory disease testing market as follows:
Global Respiratory Disease Testing Market: Product Segment Analysis
Global Respiratory Disease Testing Market: End-user Segment Analysis
Global Respiratory Disease Testing Market: Regional Segment Analysis
This report is based on in-depth qualitative and quantitative analyses of the global Respiratory Disease Testing market. Zion Research has collected and analyzed key data belong to the global Respiratory Disease Testing market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.
The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined afterconducting a detailed study of the micro and macroeconomic indicators of the market.
Various parameters have been taken into account, while estimating market size. The revenue generated by the leading industry participants in from the sales of Respiratory Disease Testing across the world has been calculated through primary and secondary research.
Zion Research employs combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include, STATISTA, trade journals, trade associations, statistical data from government websites, etc.
For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assistedin validation of findings from secondary research and to understand key trends in the Respiratory Disease Testing industry. Primary research makes up major source of data collection and validation.
We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:
Participants who typically participate in such a process include, but are not limited to:
Key opinion leaders specializing in different areas corresponding to different industry verticals
Secondary research sources that are typically referred to include, but are not limited to:
News articles, press releases and webcasts specific to companies operating in the market
Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Respiratory Disease Testing market.
Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:
The respiratory tract performs the function of inhaling oxygen from the atmosphere into the lungs, transferring of the oxygen to the blood, and exhaling carbon dioxide outside of the body. Breathing is usually habitual, controlled automatically by the respiratory center at the base of the brain. In addition, the respiratory system also helps to stabilize blood-alkaline balance (pH), remove toxic waste and regulates temperature. Respiratory diseases inhibit this usual operation of the respiratory system and are usually caused as a result of the inhalation of dangerous agents, smoking, and unhealthy lifestyles. Besides this other factors such as genetic factors, infections either indirectly or directly may also cause respiratory ailments. There are many disorders and infections of the respiratory system. Infections occur more commonly in the respiratory tract as compared to other organs in the body. The respiratory testing devices aid in detecting chronic or acute respiratory diseases; which is very necessary for the treatment to people with respiratory damages.
Respiratory tests such as spirometry, lung volume, peak flow test, imaging, blood gas test, and few other tests are used to diagnose the respiratory disease. Equipment used to detect pulmonary abnormalities hold immense potential due to increasing prevalence of various respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and pneumonia. More than 200 million people globally are suffering from asthma, and there have more than 3 million deaths worldwide due to COPD. Moreover, technological advancements and growing aged population would drive the global respiratory disease testing market. However, portable spirometers and low adoption rate of digital radiography may curb the growth of respiratory disease testing market during the forecast period. However, the budding market in Asia-Pacific can act as a potential opportunity for respiratory disease testing market during the forecast period.
Based on the type of the test, the global respiratory disease testing market has been segmented into imaging test, peak flow test, blood gas test, spirometry, lung volume test, and other tests. The imaging test segment holds the largest share of the global respiratory disease testing market. The dominance of the segment was mainly due to high demand for imaging tests, especially X-ray. In addition, doctors insist for these tests as they are considered the primary tests for diagnosis of respiratory diseases. While the spirometry test segment is projected to be the fastest growing segment during the forecast period due to its effectiveness and accurate diagnostic results in a short period of time.
The global respiratory disease testing market is segmented into three major end-user segments i.e. physician offices, hospitals, and clinical laboratories. Hospitals hold the largest market share of respiratory disease testing market in 2015. Hospitals hold more than 50% share of global respiratory disease testing market. The segment dominated the market as most of the respiratory diagnostic instruments, particularly X-ray machines are mostly available in hospitals. Moreover, doctors favor in-house diagnostic tests for their patients in comparison to outside patients.
North America holds the largest market share for respiratory disease testing in 2015. The dominance of the region was primarily due to rise popularity of portable devices, increasing the prevalence of respiratory diseases and growing demand for home health care devices and services. The respiratory disease testing market in Asia-Pacific is expected to grow at the fastest growth rate during the forecast period. Latin America is projected to expand at a noticeable growth rate during the forecast period.
Major market players in this industry are ndd Medical Technologies, Inc., Carestream Health, Inc., SDI Diagnostics, Nihon Kohden Corporation, CareFusion Corporation, Smiths Medical, COSMED, Perkin Elmer, Inc., Philips Healthcare, MGC Diagnostic Corporation, Futuremed America, Inc. and GE Healthcare among others.